The new device features an ergonomic handpiece to offer comfort for the operator and better visibility of the treatment site. Ra Medical said that Pharos is intended to improve both physician and patient experience.
The device also comes with adjustable aiming and laser beams in order to enable targeted treatments without affecting healthy tissue. Pharos’ small footprint makes it suitable for any type of treatment room.
Ra Medical Systems CEO Dean Irwin said: “The optimised Pharos is a next-generation laser that delivers what dermatologists have been asking for: faster treatments for psoriasis, vitiligo, and atopic dermatitis and an upgraded user and patient experience.”
According to the company, psoriasis, vitiligo, and atopic dermatitis impact a total of more than 25 million people living in the US. Pharos, Optimized is expected to offer a new treatment option for these conditions.
The new device has been initially displayed at the 2019 American Academy of Dermatology Summer Meeting held from 25 July to 28 July in New York, US.
Ra Medical develops excimer laser systems targeting vascular and dermatologic diseases. The company introduced Pharos in 2004 to treat dermatological conditions, including psoriasis, vitiligo, and atopic dermatitis.
The company launched DABRA later in 2017, providing an endovascular treatment for blockages caused by lower extremity vascular disease.
Both devices are powered by the company’s excimer laser technology platform, which generates 308nm light that is believed to produce a targeted immunosuppressive effect.
The company operates a 32,000ft² manufacturing facility in Carlsbad, California, US for making DABRA and Pharos excimer lasers and catheters.